Los Angeles Capital Management’s SELLAS Life Sciences SLS Stock Holding History

Los Angeles Capital Management’s Portfolio SLS Stock Details SLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$29.7K	Buy	+2,015	New	+$13.9K	﹤0.01%	1667

Other funds holding SLS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AFM

Anson Funds Management Dallas, Texas $1.68B AUM 373.57% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Jones Financial Companies Des Peres, Missouri $250B AUM 21.32% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Los Angeles Capital Management's SLS Position: Q2 2026 in Review

Los Angeles Capital Management opened a new position in SELLAS Life Sciences (SLS) in Q2 2026: 2,015 shares worth $29.7K. The stake represents ﹤0.01% of the portfolio and ranks #1667 among its holdings.

192 funds tracked by Wall St. Rank hold SLS as of Q2 2026.

Los Angeles Capital Management held 2,015 shares of SELLAS Life Sciences worth $29.7K as of Q2 2026.
SELLAS Life Sciences was a new Los Angeles Capital Management position in Q2 2026.
SELLAS Life Sciences made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q2 2026, its #1667 holding.
192 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q2 2026.

Based on Los Angeles Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.